Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026
Celcuity (Nasdaq: CELC) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on February 11-12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Celcuity (Nasdaq: CELC) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on February 11-12, 2026. CEO and co‑founder Brian Sullivan will appear for a fireside chat at 9:30 a.m. ET on February 11, 2026. A live webcast and replay will be available via the company's Investors website.
Details
News Market Reaction – CELC
On Feb 4, the day this news came out, CELC closed 3.07% below the previous close.
Data tracked by StockTitan Argus for the Feb 4 session.
Key Figures
- Summit dates
- February 11–12, 2026
- Guggenheim Emerging Outlook: Biotech Summit 2026 timing
- Fireside chat time
- 9:30 a.m. ET
- Scheduled Celcuity CEO session on February 11, 2026
- ATM capacity
- $400,000,000
- Maximum common stock under at-the-market program in S-3ASR shelf
Historical Context
-
FDA accepted NDA for gedatolisib with Priority Review and RTOR inclusion.
-
Updated Phase 3 VIKTORIA‑1 efficacy and safety data presented at SABCS.
-
Announcement of accepted oral presentation for updated VIKTORIA‑1 data.
-
Participation in Evercore Healthcare Conference with CEO fireside chat.
-
Completion of NDA submission to FDA for gedatolisib in advanced breast cancer.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 to be held in New York, New York on February 11-12, 2026.
Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, is scheduled for a fireside chat at 9:30 a.m. ET on Wednesday, February 11, 2026. A live webcast of the event will be available using this weblink https://event.summitcast.com/view/kbtj9ZAiVkB78KPZiu5dZ9/2Q8oLmGM98qWAwr5LXWSr8. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after.
About Celcuity
Celcuity is a clinical-stage biotechnology company pursuing the development of targeted therapies for the treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- ABC, has completed enrollment and the company has reported detailed results for the PIK3CA wild-type cohort and has completed enrollment of patients for the PIK3CA mutant cohort. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- ABC, is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.